On 14 July Eli Lilly and Company announced the acquisition of Protomer Technologies (“Protomer”), a private biotech company. Protomer’s proprietary peptide- and protein-engineering platform is
Eli Lilly, one of the Big Three insulin makers that’s had its eyes on diabetes technology for several years, is making moves to launch a
Lilly’s Go Dose app for adjusting Humalog (mealtime) insulin received FDA clearance in January; launch timing has not been announced. Lynn Kennedy and Adam Brown
Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes. Despite results from 6
Eli Lilly & Co says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken drugs in three just-concluded Phase III studies. According to
Eli Lilly and Company (NYSE: LLY) and the Juvenile Diabetes Research Foundation (JDRF) announced in early February 2011 that they have signed an agreement to
